Efficacy & Safety of Nasal Influenza Immunisation in Children
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The UK Departments of Health now recommend annual influenza vaccination for all children 2-7
years of age, with children over 7 years eligible for vaccination if in certain higher risk
clinical categories. Though data are available documenting the safety and immunogenicity of
LAIV in this age group, there are little data to assess efficacy and immune correlates in UK
children, and in particular atopic children. This study will enrol 200 children (and at least
200 unvaccinated household sibling controls), many with a history of asthma or recurrent
wheezing, and allow an assessment of efficacy, safety and immune correlates in these
children, and how this varies with prior administration of pandemic influenza vaccine and/or
LAIV.